Late-Life Depression

The short version

●Late-life depression is major depression occurring in older adults (commonly defined as 60–65+), and it is frequently underrecognized, undertreated, and more likely to be treatment-resistant.
●It can look different from depression earlier in life — more physical complaints, cognitive slowing ("pseudodementia"), apathy, and fewer reported feelings of sadness.
●First-line treatment is still antidepressants plus psychotherapy, but older adults respond more slowly and tolerate side effects less well, and drug interactions are a bigger concern.
●A randomized trial (TRANSFORM-3) tested esketamine nasal spray plus an antidepressant in older adults with treatment-resistant depression.¹
●Intravenous ketamine has shown benefit in late-life treatment-resistant depression in a controlled pilot,² and a systematic review supports a role while noting tolerability needs care.³
●Tovani treats depression in older adults with attention to blood pressure, dissociation tolerance, cognition, and medication interactions that matter more with age.

Clinical definition

Late-life depression refers to major depressive disorder (or clinically significant depressive symptoms) in older adults, typically defined from around age 60–65 onward, including both late-onset depression and early-onset depression that has persisted or recurred into older age. It is associated with higher rates of medical comorbidity, vascular changes ("vascular depression"), executive dysfunction, and a stronger link to cognitive decline. Presentation often skews toward somatic symptoms, apathy, and cognitive complaints rather than expressed sadness, which contributes to underdiagnosis. Treatment resistance is common, partly because of slower response, side-effect sensitivity, polypharmacy, and undertreatment.

How it differs from related conditions

vs. Major depressive disorder

Late-life depression is MDD in older adults — the same diagnosis, but with a distinct presentation, more comorbidity, and treatment considerations specific to aging.

vs. Dementia

Depression can cause reversible cognitive slowing ("pseudodementia"), and can coexist with or precede dementia; distinguishing them changes treatment, and ketamine is not a dementia treatment.

vs. Treatment-resistant depression

Late-life depression disproportionately becomes treatment-resistant, which is where ketamine/esketamine are studied — but with extra attention to safety in older bodies.

First-line treatments

Antidepressants (started low, titrated)

SSRIs/SNRIs remain first-line; "start low, go slow" reduces side effects, but adequate dose and duration are still needed.

Psychotherapy

CBT, problem-solving therapy, and interpersonal therapy are effective and avoid drug interactions — valuable in medically complex patients.

Medication review

Deprescribing interacting drugs and screening for medical/vascular contributors is part of effective treatment.

ECT for severe cases

ECT is notably effective and often well tolerated in severe or psychotic late-life depression.

When standard treatments fail

When late-life depression resists first-line treatment, escalation includes switching or augmenting antidepressants, ECT (which is particularly effective in older adults), and rapid-acting glutamatergic options. Esketamine nasal spray has been studied specifically in older adults with treatment-resistant depression, and intravenous ketamine has controlled pilot support — both requiring careful attention to blood pressure, dissociation, falls, and cognition.

Where ketamine fits

Older adults are an important group because treatment resistance is common and the slow onset of standard antidepressants is costly when time and function are limited. The dedicated TRANSFORM-3 randomized trial evaluated esketamine nasal spray plus an oral antidepressant in adults 65 and older with treatment-resistant depression,¹ and a controlled pilot of intravenous ketamine showed benefit in late-life treatment-resistant depression.² A systematic review supports a role for ketamine and esketamine in late-life depression while emphasizing that tolerability — transient blood-pressure rises, dissociation, dizziness and fall risk — deserves extra care in older patients.³ With appropriate monitoring and patient selection, it is a reasonable option for treatment-resistant late-life depression.

Where this fits with Tovani

Tovani treats depression in older adults, with the extra diligence aging warrants: reviewing the full medication list for interactions, monitoring blood pressure around dosing, considering fall risk and how dissociation may feel, and watching cognition. We also help distinguish depression-related cognitive slowing from other causes. Patients with significant cardiovascular instability or unmanaged cognitive concerns may be better served in a monitored medical setting than an at-home program.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Is ketamine safe for older adults?

It can be, with extra care. Older bodies are more sensitive to transient blood-pressure rises, dissociation, dizziness, and fall risk, and drug interactions matter more. With appropriate monitoring and patient selection it's a reasonable option for treatment-resistant late-life depression — but cardiovascular stability and cognition need attention first.

Why is depression in older adults harder to treat?

It's often underrecognized (more physical and cognitive symptoms, less expressed sadness), responds more slowly to antidepressants, and comes with more medical comorbidity and polypharmacy. That combination makes treatment resistance more common — which is where rapid-acting options become useful.

Could my memory problems be from depression?

Possibly. Depression in older adults can cause reversible cognitive slowing sometimes called "pseudodementia," which improves when the depression is treated. But depression can also coexist with or precede true dementia, so it's worth a proper evaluation to tell them apart — the treatments differ.

Is there randomized evidence for ketamine in seniors specifically?

Yes. The TRANSFORM-3 trial studied esketamine nasal spray plus an antidepressant in adults 65 and older with treatment-resistant depression, and a controlled pilot tested IV ketamine in late-life treatment-resistant depression. A systematic review supports a role while stressing careful tolerability monitoring.

References

Ochs-Ross R et al. 2020, American Journal of Geriatric Psychiatry — TRANSFORM-3 randomized trial of esketamine nasal spray plus an antidepressant in older adults with treatment-resistant depression. (PMID 31734084)
Oughli HA et al. 2023, American Journal of Geriatric Psychiatry — Controlled pilot of intravenous ketamine for late-life treatment-resistant depression. (PMID 36529623)
Sukhdeo R et al. 2026, American Journal of Geriatric Psychiatry — Systematic review of ketamine and esketamine for late-life depression, including tolerability considerations. (PMID 40930887)

Last reviewed by Dr. Ben Soffer, DO on June 2, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.